-
Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica
03 Feb 2026 08:10 GMT
… billion to bolster its oncology pipeline. AstraZeneca also expanded its … Competitive Innovation Landscape Trends
Scientific productivity is exploding, driving rapid … Roche & Co.
Genentech, Inc.
Gilead Sciences, Inc.
Nektar Therapeutics Inc.
Pfizer …
-
TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
02 Feb 2026 23:22 GMT
… inhibitor clinical pipeline include domvanalimab from Arcus Biosciences and Gilead Sciences, rilvegostomig developed … : Arcus Biosciences and Gilead Sciences
11.2.1
Product Description
11.2.2 …
-
Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight
05 Feb 2026 22:59 GMT
… Trial Analysis
Primary Sclerosing Cholangitis Pipeline Insight – 2025 report provides comprehensive … stage products, and the key Primary Sclerosing Cholangitis companies, including Gilead Sciences, Immunic …
-
Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
05 Feb 2026 13:00 GMT
… Turnover: £43.8M; partnership pipeline deal >$2B with … SMA, a severe neuromuscular disorder.
Gilead Sciences / Kite Pharma - … million to enhance its portfolio in cell and gene … cell and gene therapy products.
FDA Approved Products: Currently, there are …
-
API Manufacturing: Key Trends Reshaping the Global Market
05 Feb 2026 01:41 GMT
…
In recent months, Sanofi, AstraZeneca, Gilead Sciences, Johnson & Johnson, Takeda, GSK … predict equipment failures, optimize production parameters, improve product quality, and reduce … wave of investment and competitive pipeline build-out.”
Flamma’s …
-
GSK’s oncology and HIV drugs drive 7% sales rise in 2025
04 Feb 2026 19:33 GMT
… its HIV portfolio in 2025, Citi analysts expect that Gilead Sciences will … company to success through its pipeline, which it will look … the launch of next-wave products, while accelerating R& … 2027 and 2028. Dolutegravir products brought in a total of …
-
As U.S. Life Sciences Market Recovers, “Definite Dichotomy” Among Companies
04 Feb 2026 17:57 GMT
… down the number of products in the pipeline. And that’s … by companies with significant product portfolios and major revenue. … .
In the Bay Area, Gilead Sciences and [Roche subsidiary] Genentech … and with production. In a couple of production environments, we …
-
Pharmaceuticals Market to Register a Robust CAGR of 8.19% During the 2026–2034 Forecast Period
04 Feb 2026 13:00 GMT
… the therapeutic landscape.
Pharmaceutical products are essential for disease prevention … K.)
Amgen Inc. (U.S.)
Gilead Sciences, Inc. (U.S.)
Takeda … supporting market expansion. Furthermore, continuous pipeline development, strategic collaborations, and …
-
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
04 Feb 2026 12:00 GMT
… creating a diversified portfolio of biotech and pharmaceutical product revenue streams … development stage or commercial biopharmaceutical products and licensing our technology … Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more …
-
Mirum doubles down on diversified rare disease strategy
04 Feb 2026 04:33 GMT
… bought Travere Therapeutics’ bile acid product portfolio, which included the rare disease … , Sanofi gobbled up Blueprint Medicines, Gilead Sciences snapped up CymaBay Therapeutics, and … therapies, added to its pipeline and portfolio when it bought the rare …
About
© 1995-2026